Sarepta Therapeutics (SRPT) Sees Wild Late-Day Action
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Wedbush Sees Sarepta Therapeutics (SRPT) Filing for Accelerated Approval of Eteplirsen
April 15, 2013 1:06 PM EDTWedbush reiterated its Outperform rating and $60 price target on Sarepta Therapeutic (NASDAQ: SRPT) following two presentations at the World Orphan Drug Congress last week. Insight from the Congress suggests an accelerated approval filing of eteplirsen is likely, analysts led by Christopher N. Marai, Ph.D said.
"SRPT's main presentation focused on the potential regulatory path forward for follow-on compounds to treat DMD caused by mutations in rarer exons where running trials could be impractical," the Marai-led group... More
